2017-02-27,MediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected For Presentation At The 5th Quadrennial Meeting Of The World Federation Of Neuro-Oncology Societies In Zurich, Switzerland
2017-02-07,MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted For Presentation At The American Academy Of Neurology (AAN) 69th Annual Meeting In Boston
2017-02-06,MediciNova Announces Positive Findings From Completed Trial Of MN-166 (ibudilast) In Methamphetamine Dependence Presented At The 50th Winter Conference On Brain Research
2017-02-01,MediciNova To Attend Mizuho Healthcare Conference In New York
2017-01-30,Medicinova is Now Oversold (MNOV)
2017-01-23,MediciNova Announces Publication Of Positive Findings On MN-166 (ibudilast) In Alcohol Dependence
2016-12-29,Oversold Conditions For Medicinova (MNOV)
2016-12-20,MediciNova Announces European Commission Grants Orphan Medicinal Product Designation For MN-166 (ibudilast) For Amyotrophic Lateral Sclerosis
2016-12-19,MediciNova Announces Phase 2b Trial Of MN-166 (ibudilast) In Progressive MS Will Continue As Planned Following DSMB Review Of Interim Efficacy Analysis
2016-12-14,MediciNova Added To NASDAQ Biotechnology Index
2016-12-09,MediciNova Announces Exploratory Interim Clinical Outcomes Data From Clinical Trial Of MN-166 (ibudilast) In ALS Presented At The 27th International Symposium On ALS/MND In Dublin, Ireland
2016-11-15,Noteworthy Tuesday Option Activity: MNOV, ESPR, PAY
2016-11-14,MediciNova To Present At The Piper Jaffray Healthcare Conference In New York
2016-11-10,MediciNova Announces European Medicines Agency Recommends Orphan Medicinal Product Designation For MN-166 (ibudilast) For Amyotrophic Lateral Sclerosis
2016-11-07,MediciNova To Attend Global Mizuho Investor Conference In New York
2016-10-30,MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted For Presentation At The 27th International Symposium On ALS/MND In Dublin, Ireland
2016-10-11,MediciNova Announces FDA Granted Orphan Drug Designation To MN-166 (ibudilast) For Amyotrophic Lateral Sclerosis
2016-09-25,Options On MediciNova Common Stock Listed On CBOE
2016-08-31,Medicinova Enters Oversold Territory (MNOV)
2016-07-24,MediciNova Receives Notice Of Allowance For New Patent Covering MN-001 And MN-002 For The Treatment Of Fibrosis
2016-07-13,MediciNova Announces Initiation Of Interim Efficacy Analysis In Phase 2b Trial Of MN-166 (ibudilast) In Progressive MS
2016-06-29,MediciNova Announces Results From Clinical Trial Of MN-166 (ibudilast) In Alcohol Dependence Presented At The 39th Annual Scientific Meeting Of The Research Society On Alcoholism In New Orleans, Louisiana
2016-06-26,MediciNova Added To Russell 3000® Index And Russell Global Index
2016-05-25,MediciNova Announces Additional Results From The Completed Trial Of MN-166 (ibudilast) In Alcohol Dependence To Be Presented At The 39th Annual Scientific Meeting Of The Research Society On Alcoholism In New Orleans, Louisiana
2016-04-20,MediciNova Announces Interim Data From Clinical Trial Of MN-166 (ibudilast) In ALS Presented At The American Academy Of Neurology (AAN) 68th Annual Meeting In Vancouver, Canada
2016-03-30,MediciNova Announces Publication Of Positive Findings From Completed Phase 1b Clinical Trial Of MN-166 (ibudilast) In Methamphetamine Dependence
2016-03-27,MediciNova Receives Notice Of Allowance For New Patent Covering MN-001 In China
2016-03-23,MediciNova Receives Notice Of Allowance For New Patent Covering MN-001 And MN-002 For The Treatment Of Hypertriglyceridemia, Hypercholesterolemia, And Hyperlipoproteinemia
2016-03-22,FDA Grants Fast Track Designation For MediciNova's MN-166 (ibudilast) For Progressive Multiple Sclerosis
2016-03-07,MediciNova Receives Notice Of Allowance For New Patent Covering MN-166 (ibudilast) For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)
2016-03-06,MediciNova Announces Positive Findings From A Completed Phase 2 Trial Of MN-166 (ibudilast) In Opioid Dependence At The Behavior, Biology And Chemistry: Translational Research In Addiction Meeting In San Antonio, Texas
2016-02-22,MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted For Dual Presentation At The American Academy Of Neurology (AAN) 68th Annual Meeting In Vancouver, Canada
2016-02-11,MediciNova Announces Presentation Regarding MN-166 (ibudilast) And Methamphetamine Dependence At The Behavior, Biology And Chemistry Annual Meeting And Symposium In San Antonio, Texas
2016-02-07,MediciNova Announces Presentation Of Data From The Completed Phase 2 Trial Of MN-166 (ibudilast) In Opioid Dependence At The Behavior, Biology And Chemistry Annual Meeting And Symposium In San Antonio, Texas
2016-01-27,MediciNova Receives Notice Of Allowance For New Patent Covering MN-001 And MN-002 For The Treatment Of Advanced NASH With Fibrosis
2016-01-18,FDA Grants Rare Pediatric Disease Designation To MediciNova's MN-166 (ibudilast) For The Treatment Of Krabbe Disease
2016-01-13,MediciNova Receives Notice Of Allowance For New Patent Covering MN-029 (denibulin) Di-hydrochloride In Europe
2015-12-16,FDA Grants Fast Track Designation For MediciNova's MN-166 (ibudilast) For The Treatment Of Amyotrophic Lateral Sclerosis
2015-12-14,MediciNova Receives Notice Of Allowance For New Patent Covering MN-029 (denibulin) Di-hydrochloride In China
2015-12-13,MediciNova Announces Positive Interim Safety And Clinical Outcomes Data From Clinical Trial Of MN-166 (ibudilast) In ALS Presented At The 26th International Symposium On ALS/MND In Orlando, FL
2015-12-09,MediciNova Announces Positive Findings From A Clinical Trial Of MN-166 (ibudilast) In Alcohol Use Disorder (AUD) Reported At The American College Of Neuropsychopharmacology (ACNP)'s 54th Annual Meeting
2015-12-06,MediciNova Announces Presentation Regarding Clinical Trial Of MN-166 (ibudilast) In ALS At The 6th Annual California ALS Pac10 And Research Network Meeting At UCSD, La Jolla, California 
2015-11-19,MediciNova To Initiate Clinical Trial Evaluating MN-001 In NASH Patients With Hypertriglyceridemia 
2015-11-10,MediciNova Receives Notice Of Allowance For New Patent Covering MN-221 (bedoradrine) For The Treatment Of Irritable Bowel Syndrome In Japan
2015-11-09,FDA Approves A New Clinical Protocol To Evaluate The Effects Of MN-166 (ibudilast) On A Biomarker Of ALS; MediciNova Plans To Initiate A Clinical Trial With MGH (Massachusetts General Hospital)  
2015-11-04,MediciNova Announces Interim Data From Clinical Trial Of MN-166 (ibudilast) In ALS To Be Presented At The 14th Annual NEALS (Northeast Amyotrophic Lateral Sclerosis) Meeting In Clearwater Beach, Florida
2015-10-13,MediciNova To Present Preclinical Data On MN-166 (ibudilast) At The 26th International Symposium On ALS/MND In Orlando, FL
2015-10-09,MediciNova To Initiate Clinical Trial Of MN-001 (tipelukast) In IPF
2015-09-24,MediciNova To Present At The Ladenburg Thalmann 2015 Healthcare Conference
2015-09-10,FDA Grants Fast Track Designation For MediciNova's MN-001 (tipelukast) For The Treatment Of Idiopathic Pulmonary Fibrosis
2015-09-02,MediciNova Announces First Advanced ALS Patient Using Non-Invasive Ventilation Support Enrolled In Phase 2 Clinical Trial Of MN-166 (ibudilast)
2015-08-24,MediciNova Announces Closing Of Underwritten Public Offering Of Common Stock
2015-08-18,MediciNova Announces Pricing Of Underwritten Public Offering Of Common Stock
2015-08-18,MediciNova Announces Proposed Underwritten Public Offering Of Common Stock
2015-07-28,MN-166 (ibudilast) ALS Abstract Accepted For Presentation At The 26th International Symposium On ALS/MND In Orlando, FL: Interim Safety And Clinical Outcomes To Be Presented
2015-07-27,MediciNova Announces FDA Approval Of The Second Phase 2 Protocol For MN-001 In NASH Which Targets NASH Patients With Hypertriglyceridemia
2015-07-21,MediciNova Announces Update On Development Plans For MN-001 In IPF
2015-06-30,MediciNova Announces The Completion Of Enrollment In Clinical Trial Of MN-166 (ibudilast) In Alcohol Dependence
2015-06-24,MediciNova Announces Presentation Of Interim Data From Clinical Trial Of MN-166 (ibudilast) In Alcohol Dependence At The 38th Annual RSA (Research Society On Alcoholism) Scientific Meeting
2015-06-16,MediciNova Announces New Article Published On MN-166 (ibudilast) In Addiction Biology
2015-06-12,MediciNova Announces Randomization Of 255 Subjects Completed In Phase 2b Trial Of MN-166 (ibudilast) In Progressive MS
2015-06-03,MediciNova Announces FDA Granted Orphan Drug Designation To MN-166 (ibudilast) For Krabbe Disease
2015-05-07,MediciNova Announces Full Enrollment In Phase 2b Trial Of MN-166 (ibudilast) In Progressive MS
2015-04-23,Baseline Characteristics Of 228 Subjects Enrolled In MediciNova's Phase 2b Trial Of MN-166 (ibudilast) In Progressive MS Presented At The American Academy Of Neurology (AAN) 67th Annual Meeting
2015-04-21,MediciNova Announces Positive Interim Safety Data From Clinical Trial Of MN-166 (ibudilast) In ALS
2015-04-16,MedicNova (MNOV) Stock is Gaining Today After Drug Receives Fast Track Designation
2015-04-16,Tokyo Stock Exchange Announces New Rule Affecting Trading Of MediciNova Stock In Japan
2015-04-16,FDA Grants Fast Track Designation For MediciNova's MN-001 (tipelukast) For The Treatment Of NASH With Fibrosis
2015-03-02,MN-166 (Ibudilast) Effects In Opioid Dependence Selected For Presentation At The 77th Annual Meeting Of The College On Problems Of Drug Dependence In Phoenix, Arizona
2015-02-25,MediciNova's MN-001 (tipelukast) NASH With Advanced Fibrosis Abstract Accepted For Presentation At The AASLD And Industry Colloquium: Novel Targets And Therapies In Liver Disease In Durham, North Carolina
2015-02-16,MediciNova Provides Update On Clinical Trial Of MN-166 (Ibudilast) In ALS
2015-02-10,MediciNova Announces FDA Approval Of Protocol For Phase 2 Trial Of MN-001 In IPF
2015-02-03,MediciNova Receives Notice Of Allowance For New Patent Covering MN-001 And MN-002 For The Treatment Of NASH
2015-02-02,MN-166 (ibudilast) ALS Abstract Accepted For Dual Presentation At The American Academy Of Neurology (AAN) 67th Annual Meeting In Washington, DC
2015-02-01,MN-166 (ibudilast) Progressive MS Abstract Accepted For Presentation At The American Academy Of Neurology (AAN) 67th Annual Meeting In Washington, DC
2015-01-29,MediciNova Receives New Patent Covering MN-029 (denibulin) Di-hydrochloride In Japan
2015-01-28,MediciNova Announces An Open Investigational New Drug (IND) Application For MN-001 In NASH
2014-12-09,MediciNova Receives Notice Of Allowance For New Patent Covering MN-001 And MN-002 For The Treatment Of Liver Disorders
2014-12-02,Five Biotech Firms Whose Stock-Promoting Efforts Didn't Pay Off
2014-10-23,U.S. Centers For Disease Control And Prevention (CDC) Supports Recruitment For MediciNova's Clinical Trial Of MN-166 (Ibudilast) In ALS
2014-10-22,MediciNova Announces FDA Granted Orphan Drug Designation To MN-001 (tipelukast) For Idiopathic Pulmonary Fibrosis (IPF)
2014-10-08,MediciNova Receives Feedback From FDA Regarding Study Protocol For Phase 2 Trial Of MN-001 (tipelukast) In NASH
2014-10-07,It's True, Small-Cap Biotech Stocks Are Acting Badly These Days
2014-10-06,MediciNova's MN-001 (tipelukast) NASH Abstract Selected For Late-Breaking Session At The 65th Annual AASLD Meeting In Boston
2014-09-29,Overview Of MediciNova's Clinical Trial Of MN-166 (ibudilast) In ALS To Be Presented At The 13th Annual NEALS Meeting
2014-09-23,MediciNova Provides Update On Phase 2b Trial Of MN-166 (ibudilast) In Progressive MS
2014-09-07,MediciNova Announces New NIDA Grant For MN-166 (ibudilast) In Opioid Dependence
2014-09-02,3 Stocks Raising The Drugs Industry Higher
2014-09-01,MediciNova To Present Data On MN-001 (tipelukast) For The Treatment Of Idiopathic Pulmonary Fibrosis (IPF) During The 18th International Colloquium On Lung And Airway Fibrosis (ICLAF)
2014-08-26,3 Stocks Pushing The Drugs Industry Higher
2014-08-25,MediciNova To Initiate Clinical Trial Of MN-166 (ibudilast) In ALS
2014-08-18,MediciNova Announces Positive Interim Results Of Phase 2a Study Of MN-166 (ibudilast) In Opioid Dependence
2014-08-11,MediciNova Receives Notice Of Allowance For New Patent Covering MN-001 And MN-002 For The Treatment Of Nonalcoholic Fatty Liver Disease
2014-08-05,3 Stocks Pushing The Drugs Industry Lower
2014-08-05,MediciNova Announces Positive Results Of MN-001 In Advanced NASH Mouse Model; MediciNova Requests A Meeting With FDA
2014-07-30,3 Drugs Stocks Pushing The Industry Higher
2014-07-07,MediciNova To Present Data On MN-001 For The Treatment Of NASH (Nonalcoholic Steatohepatitis) During The JDDW 2014 (Japan Digestive Disease Week 2014)
2014-06-11,MediciNova Announces Positive Results In Study Of MN-001 In Mouse Model Of Pulmonary Fibrosis
2014-04-08,MediciNova Appoints Yoshio Ishizaka To Its Board Of Directors
2014-04-08,MediciNova Announces Management Appointment
2014-01-17,Five Worst, Pandering Drug Stocks of J.P. Morgan Healthcare Confab Week
2014-01-14,MediciNova Announces Positive Results In NASH Mouse Model With MN-001 And Prepares To Initiate Phase 2 Trial In The U.S.
2013-11-11,MediciNova Receives New Patent Covering MN-221 In Irritable Bowel Syndrome
2013-11-07,MediciNova Reports Third Quarter 2013 Results
2013-10-16,MediciNova Appoints Yutaka Kobayashi To Its Board Of Directors
2013-10-16,MediciNova Appoints Geoffrey O'Brien As Vice President
2013-10-06,MediciNova Receives Notice Of Allowance For New Patent Covering MN-029 (denibulin) Di-hydrochloride
2013-08-25,National Institute On Alcohol Abuse And Alcoholism Funds New UCLA Clinical Trial Of MediciNova's MN-166 In Treating Alcoholism
2013-08-08,MediciNova Reports Second Quarter 2013 Results
2013-07-18,MediciNova Announces Initiation Of A Cooperative Phase 2b Trial Of MN-166 In Progressive Multiple Sclerosis
2013-06-18,UCLA Presents Data On MediciNova's MN-166 In Methamphetamine Addiction At The 75th Annual Meeting Of The College On Problems Of Drug Dependence
2013-05-08,MediciNova Reports First Quarter 2013 Results
2013-03-28,MediciNova Reports Fourth Quarter And Full Year 2012 Results
2013-03-20,MediciNova Announces MN-166 (ibudilast) Opioid Withdrawal And Analgesia Data Presentation At The American Academy Of Neurology Annual Meeting
2013-02-25,FDA Grants Fast Track Designation For MediciNova's MN-166 (ibudilast) For The Treatment Of Methamphetamine Dependence
2013-01-03,MediciNova Provides Development Update
2012-10-22,MediciNova Meets With FDA For End-of-Phase 2 Meeting For MN-221 For The Treatment Of Acute Exacerbations Of Asthma
2012-09-04,NIH Funds UCLA Phase 2 Study Of MediciNova's MN-166 In Treating Drug Addiction
2012-08-28,MediciNova To Present At The Rodman & Renshaw Annual Global Investment Conference On September 11, 2012
2012-08-23,MediciNova Announces Positive Preliminary Results From A Multi-Day, Repeat-Dose Clinical Trial With MN-221 In Chronic Obstructive Pulmonary Disease Patients
2012-08-20,MediciNova Enters Into A $20 Million Common Stock Purchase Agreement With Aspire Capital Fund
2012-08-09,MediciNova Reports Second Quarter 2012 Results
2012-05-04,5 Stocks Under $10 Set to Soar
2011-03-23,MediciNova Prices $8.25 Million Public Offering Of Common Stock And Warrants
2011-03-23,MediciNova Announces Proposed Public Offering Of Common Stock And Warrants
2011-03-21,5 Health Care Stocks With Upside
2011-03-09,MediciNova Receives A Notice Of Allowance For A Method Of Treating Drug Addiction Or Dependence
2011-03-03,Joint Venture Announced
2011-02-03,10 Pharma Stocks With 100% Buy Ratings
2010-12-13,Columbia University/New York State Psychiatric Institute And MediciNova Report Preliminary Safety And Efficacy Of Ibudilast In Heroin-dependent Volunteers
2010-11-15,MediciNova Reports Third Quarter 2010 Results
2010-10-28,MedicNova Announces Poster Presentations At Annual Meeting Of The American College Of Chest Physicians
2010-10-19,MediciNova's MN-166 Program Recognized As One Of Windhover's Top 10 Neuroscience Projects To Watch
2010-09-27,UCLA Initiates A NIDA-Supported Phase 1b Study With Ibudilast In Methamphetamine-Dependent Volunteers
2010-09-02,MediciNova To Present At The Rodman And Renshaw Annual Global Investment Conference
2010-08-16,MediciNova Reports Second Quarter 2010 Results
2010-08-02,$5 Stocks That Analysts Expect to Double
2010-07-12,MediciNova Announces Estimated Timing Of Payments To Former Avigen Stockholders
2010-07-07,Insight On MediciNova's MN-166 Mechanism Of Action Reported In Proceedings Of The National Academy Of Sciences
2010-07-06,MediciNova Nets $9.5 Million From Settlement Of Auction Rate Securities Held By UBS
2010-06-14,MediciNova Appoints Michael Coffee As Chief Business Officer
2010-05-11,MediciNova Secures $15 Million Debt Facility From Oxford Finance Corporation
2010-04-23,MediciNova Releases Notice Of Pendency And Settlement Of Class Action
2009-01-09,Latest News in Activist Investing
,
